DexCom (DXCM)
(Delayed Data from NSDQ)
$289.08 USD
+8.45 (3.01%)
Updated May 27, 2022 04:00 PM ET
After-Market: $288.83 -0.25 (-0.09%) 7:06 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DXCM 289.08 +8.45(3.01%)
Will DXCM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DXCM based on the 1-3 month trading system that nearly triples the S&P 500.
Zacks News for DXCM
Here's Why You Should Hold on to DexCom (DXCM) Stock Now
Are Options Traders Betting on a Big Move in DexCom (DXCM) Stock?
DXCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
DexCom (DXCM) Q1 Earnings Miss, Revenues Beat Estimates
DexCom (DXCM) Misses Q1 Earnings Estimates
Is a Surprise Coming for DexCom (DXCM) This Earnings Season?
Other News for DXCM
DexCom Inc. stock falls Thursday, underperforms market
Lake Street says diabetes industry consolidation unlikely to hurt Tandem
DexCom Inc. stock falls Wednesday, underperforms market
Wednesday Sector Laggards: Healthcare, Utilities
Snap, Nautilus fall; Nordson, Insulet rise